The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT).
Jenny J. Ko
No relevant relationships to disclose
Wanling Xie
No relevant relationships to disclose
Daniel Yick Chin Heng
Consultant or Advisory Role - AVEO; Bayer; Novartis; Pfizer
Nils Kroeger
No relevant relationships to disclose
Jae-Lyun Lee
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Bayer
Brian I. Rini
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Onyx; Pfizer
Research Funding - GlaxoSmithKline; Pfizer
Jennifer J. Knox
No relevant relationships to disclose
Georg A. Bjarnason
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer
Lauren Christine Harshman
Consultant or Advisory Role - Novartis; Pfizer
Honoraria - Pfizer
Research Funding - Pfizer
Sumanta Kumar Pal
No relevant relationships to disclose
Takeshi Yuasa
No relevant relationships to disclose
Martin Smoragiewicz
No relevant relationships to disclose
Frede Donskov
Research Funding - Novartis
Aristotelis Bamias
No relevant relationships to disclose
Lori Wood
Consultant or Advisory Role - Novartis; Pfizer
Research Funding - GlaxoSmithKline; Novartis; Pfizer
D. Scott Ernst
No relevant relationships to disclose
Neeraj Agarwal
No relevant relationships to disclose
Ulka N. Vaishampayan
Honoraria - GlaxoSmithKline; Novartis; Pfizer
Research Funding - GlaxoSmithKline; Novartis; Pfizer
Sun Young Rha
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Pfizer
Research Funding - Bayer; Novartis
Toni K. Choueiri
Consultant or Advisory Role - AVEO; Bayer; Genentech; GlaxoSmithKline; Novartis; Onyx; Pfizer
Research Funding - Pfizer